Peptide Compounding: What a Pharmacy Should Explain Before Dispensing

A named prescriber, an identifiable dispensing pharmacy and a clear route for reporting problems give patients someone to hold accountable. The October 28 HHS peptide announcement raises a practical question: what should that pharmacy be able to explain about the medicine it supplies?

The October 28 HHS announcement brings that argument into focus. Its federal notice describes an enforcement-discretion policy for certain peptide ingredients compounded under section 503A, while rulemaking continues. The notice calls the policy a draft and acknowledges the risks of compounded medicines.

A purity percentage can tell a reader something about what a particular test measured. It cannot answer every question about a finished medicine. Identity, strength, contamination, stability and the conditions of preparation are separate issues.

For a sterile preparation, an analytical purity result alone cannot establish sterility. Nor does a test on a raw ingredient automatically demonstrate the quality of every finished batch. The sample, method and stage of manufacture all affect what can reasonably be concluded.

The FDA's explanation of compounded-drug risks identifies contamination and incorrect amounts of active ingredient as potential problems. It also notes that poor compounding practices can cause serious injury. A pharmacy label is a reason to ask more precise questions, rather than a reason to stop asking them.

A facility's regulatory registration is not the same thing as approval of each medicine it handles. An ingredient's inclusion within a compounding framework is another distinct matter. A specific drug's approval for an indication is different again.

These records are often compressed into phrases such as FDA registered or pharmacy grade. A useful explanation should name the entity or product to which the statement applies and identify the record that supports it.

The federal notice states that compounded drugs are not FDA-approved and do not receive the same premarket review for safety, effectiveness and quality. That remains relevant even when a compounded preparation serves an individual medical need.

Before dispensing, ask the clinician and pharmacist to explain:

• The exact ingredient, formulation and intended use.
• Why a compounded preparation is being proposed and what established alternatives exist.
• Which quality checks apply to the finished batch, including strength and, where relevant, sterility.
• The product-specific storage instructions, beyond-use date and contact for a suspected problem.
• The follow-up plan and the limits of the human evidence.

These are questions to put to the responsible professionals, rather than a claim that every pharmacy follows identical procedures.

A clear answer should distinguish what is known about the substance from what has been verified about the particular preparation. It should also identify the limits of available evidence. A patient should not have to infer all of that from a certificate, a logo or a social-media endorsement.

We have not independently assessed any individual pharmacy or product for this report. Nothing in the announcement establishes the quality of every product marketed under one of the six peptide names.

The HHS appendix and any later revisions are the place to verify the exact covered substances and conditions. This report could verify the public-inspection notice but could not retrieve the linked appendix, so it does not reproduce a definitive compliance checklist.

The notice says HHS may revisit its interim approach if safety signals or product-quality problems arise. That provision makes ongoing monitoring part of the story.

A more accountable supply route could be a worthwhile change. The clinical question remains whether a particular preparation improves a defined outcome enough to justify its risks. That requires evidence about patients, not simply evidence that a vial passed through a more recognisable channel.

FDA: understanding the risks of compounded drugs

HHS draft-policy public-inspection notice

This article reports on policy and research reviewed on October 29, 2026. It is for educational purposes only and is not medical advice. No individual product, seller or treatment is endorsed.